Omalizumab is a humanized monoclonal antibody derived from recombinant DNA that selectively binds to immunoglobulin (IgE).
Omalizumab binds to IgE and prevents its interaction with the high-affinity FcεRI receptor. Thus, there is a decrease in the amount of free IgE, which is the trigger for the cascade of allergic reactions.
Omalizumab is the only class of biological anti-IgE therapy recommended for the treatment of atopic bronchial asthma, helps to eliminate or reduce the use of glucocorticosteroids, and also reduces the number and frequency of exacerbations.
ЛП-006487 от 30.09.2020